Know Cancer

forgot password

A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

Phase 2
21 Years
Open (Enrolling)
Neuroblastoma, Sarcoma

Thank you

Trial Information

A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

Inclusion Criteria:

- Patients must have histologically confirmed relapsed/refractory Ewing's sarcoma or

- Patients must have measurable disease

- Patients must be ≤ 21 years of age at time of diagnosis

- Life expectancy ≥ 3 months

- Lansky or Karnofsky performance ≥ 70%

- Written informed consent

- Organ and marrow function defined as follows:

Hematologic function, as follows

- Absolute neutrophil count ≥ 1000/μL

- Platelets ≥ 100 x 109/L (without transfusion < 14 days before enrollment) Hemoglobin
≥ 9 gm/dl

Renal function, as follows:

- Serum creatinine ≤ ULN for age. Refer to Appendix H for normal values for serum
creatinine in children.

- If serum creatinine above these values, the calculated creatinine clearance or
radioisotope GFR must be ≥ 60 ml/min/1.73 m2

- Urinary protein < 2+ (unless total quantitative protein is < 500 mg protein/day as
determined by 24 H urine collection) for pediatric patients please refer to the CTCAE
V4.0 for values.

Hepatic function, as follows:

- Total bilirubin ≤ 1.5x ULN

- AST and ALT ≤ 2.5x ULN for institution or ≤ 5x ULN for institution if clearly
attributable to liver metastases

- Albumin ≥ 2.5 g/dl. Coagulation: INR ≤ 1.5x ULN.

- Prior Treatment: Patients must have recovered from the acute toxic effects of all
prior chemotherapy, immunotherapy, or radiation therapy prior to entry on study.
Patients must have had at least one prior treatment regimen. Patients may have
received treatment previously with cyclophosphamide or topotecan but no prior

- Myelosuppressive chemotherapy: Two weeks must have elapsed since administration of
previous chemotherapy.

- Biologic agents: At least 2 weeks must have elapsed since the completion of therapy
with a monoclonal antibody. Seven days must have elapsed since the last dose of

- Radiation therapy: For all patients, ≥ 4 weeks must have elapsed for local XRT; ≥ 6
months must have elapsed if prior radiation to ≥ 50% of the pelvis or if substantial
bone marrow irradiation. Patients with a history of prior radiation with field
including the heart (e.g. mantle) will be excluded.

- Stem cell transplant: Patients who have undergone prior stem cell transplantation
will not be excluded from study entry. At least 3 months must have elapsed since
autologous or allogeneic stem cell transplantation. Patients must have no evidence of
active graft versus host disease.

Exclusion Criteria:

- Patients with centrally-located pulmonary or mediastinal primary tumors or metastases
adjacent to or invading large blood vessels.

- Prior left chest wall irradiation or a cumulative anthracycline dose of greater or
equal to 300 mg/m2, unless the ejection fraction or fraction shortening is within
normal institutional limits, in which case the patient can be enrolled.

- Inability to comply with study and/or follow-up procedures

- Life expectancy of less than 3 months

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study other than a Genentech-sponsored
bevacizumab cancer study

- Active second malignancy, other than superficial basal cell and superficial squamous
(skin) cell, or carcinoma in situ of the cervix within last five years

- History of other malignancies, except for other solid tumors curatively treated with
no evidence of disease for > 3 years prior to enrollment.

- Known infection with human immunodeficiency virus (HIV).

- Uncontrolled hypertension (sBP >150 mmHg and/or diastolic BP > 100 mmHg, found on two
consecutive measurements separated by a one week period of time despite adequate
medical support).

- Prior history of hypertensive crisis or hypertensive encephalopathy.

- New York Heart Association (NYHA) Grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to Day - 3.

- History of stroke or transient ischemic attack within 6 months prior to Day -3.

- Known CNS disease, except for treated brain metastases.

- Treated brain metastases are defined as having no evidence of progression or
hemorrhage after treatment and no ongoing requirement for dexamethasone, as
ascertained by clinical examination and brain imaging (MRI or CT) during the
screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain
metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma
Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating
physician. Patients with CNS metastases treated by neurosurgical resection or brain
biopsy performed within 3 months prior to Day -3 will be excluded.

- Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or
recent peripheral arterial thrombosis) within 6 months prior to Day -3.

- History of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 1 month
prior to Day -3.

- Evidence of bleeding diathesis or significant coagulopathy (in the absence of
therapeutic anticoagulation).

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day -3 or anticipation of need for major surgical procedure during the
course of the study. (A major procedure constitutes an invasive procedure which
requires general anesthetic support, hospitalization, and supportive care such as
laparotomy, laminectomy, etc.)

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to Day 1. (Minor surgical procedures include
minimally invasive procedures such as fine needle aspiration, core biopsy, etc
requiring little if any supportive care excluding lumbar puncture and bone marrow

- History of abdominal fistula or gastrointestinal perforation within 6 months prior to
Day -3.

- Serious, non-healing wound, active ulcer, or untreated bone fracture.

- Thrombolytics or treatment doses of warfarin within 28 days of initiating treatment.
Patients who require low dose warfarin for central venous catheter patency are
allowed to enter if their dose is < 2 mg per day total AND their International
Normalized Ratio (INR) is ≤ 1.5.

- Patients requiring treatment doses of heparin for any reason. The use of heparin
flushes for maintenance of central venous catheters is permitted

- Patients requiring aspirin > 325 mg per day or non-steroidal anti-inflammatory
medications known to inhibit platelet function. Patients taking cyclooxygenase-2
inhibitors (COX-2) inhibitors are allowed to enroll.

- History or clinical evidence of deep venous thrombosis including pulmonary embolus
within 6 months of treatment.

- Patients with proteinuria > 1+ on urine dipstick or UPC ratio ≥ 1.0 at screening. If
>1+ proteinuria is detected on surveillance, a 24-hour collection must be performed
if eligibility is desired. Patients with a 24-hour urine protein content of ≤ 500 mg
are eligible.

- Known hypersensitivity to any component of bevacizumab.

- Pregnancy (positive pregnancy test) or lactation. (An effective means of
contraception (men and women) in subjects of child-bearing potential must be used.)

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:


Outcome Description:

as measured by objective response rate (CR/PR) after 2 cycles of treatment and duration of response. after 2 cycles of treatment and duration of response according to the Revised RECIST guideline (version 1.1)

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Tanya Trippett, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

December 2011

Completion Date:

December 2014

Related Keywords:

  • Neuroblastoma
  • Sarcoma
  • Ewing's sarcoma
  • 11-183
  • Neuroblastoma
  • Sarcoma, Ewing's
  • Neuroectodermal Tumors, Primitive, Peripheral
  • Sarcoma



MD Anderson Cancer Center Houston, Texas  77030-4096
Memorial Sloan-Kettering Cancer Center New York, New York  10021
Phoenix Children's Hospital Phoenix, Arizona  85016-7710
Dana Farber Cancer Institute Boston, Massachusetts  02115
John Hopkins Medical Center Baltimore, Maryland  21287
Pennsylvania State University College of Medicine Hershey, Pennsylvania  17033
Children's Mercy Hospital & Clinics Kansas City, Missouri  64108
University of Colorado Health Sciences Center and The Children's Hospital Aurora, Colorado  80045
MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children Orlando, Florida  32806